CT102 growth factor mixture data

CURE reported in Wounds that in a 70-patient, 20-week Phase II clinical study of CT102 in chronic, non-healing diabetic foot ulcers, a 0.01 dilution of the mixture healed 80 percent of wounds, versus 29 percent in patients treated with saline solution (p=0.01). Patients received dilutions of 0.01 (n=15), 0.033 (n=13), 0.1 (n=21) or saline (n=21). All patients received treatment at CURE's wound care clinics.

CT102 is a homologous platelet-derived solution of a combination of growth factors. The best results were obtained with the lowest dose of CT102 compared to placebo. At the final visit, the mean decrease in wound volume for all patients receiving CT102 was 94.9 percent versus 82.7 percent for placebo (p=0.005). Mean decrease in area was 93 percent for CT102 and 77.1 percent for placebo (p=0.002). Median time to 80 percent healing using CT102 was 46 days versus 92 days for placebo (p=0.037). CT102 is in Phase III trials in Europe and Phase II trials in the U.S. ...